Akebia Therapeutics Inc (NASDAQ: AKBA) kicked off on Tuesday, up 0.26% from the previous trading day, before settling in for the closing price of $3.84. Over the past 52 weeks, AKBA has traded in a range of $1.07-$4.08.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 32.58% over the last five years. While this was happening, its average annual earnings per share was recorded 82.42%. With a float of $251.62 million, this company’s outstanding shares have now reached $261.64 million.
The firm has a total of 181 workers. Let’s measure their productivity. In terms of profitability, gross margin is 67.77%, operating margin of -11.91%, and the pretax margin is -24.51%.
Akebia Therapeutics Inc (AKBA) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Drug Manufacturers – Specialty & Generic Industry. The insider ownership of Akebia Therapeutics Inc is 4.19%, while institutional ownership is 36.62%. The most recent insider transaction that took place on Jun 30 ’25, was worth 151,622. In this transaction SVP, CFO, CBO & Treasurer of this company sold 41,314 shares at a rate of $3.67, taking the stock ownership to the 503,586 shares. Before that another transaction happened on Jun 30 ’25, when Company’s Officer proposed sale 41,314 for $3.67, making the entire transaction worth $151,622.
Akebia Therapeutics Inc (AKBA) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 82.42% per share during the next fiscal year.
Akebia Therapeutics Inc (NASDAQ: AKBA) Trading Performance Indicators
Take a look at Akebia Therapeutics Inc’s (AKBA) current performance indicators. Last quarter, stock had a quick ratio of 2.02. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.47.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.22, a number that is poised to hit -0.01 in the next quarter and is forecasted to reach 0.09 in one year’s time.
Technical Analysis of Akebia Therapeutics Inc (AKBA)
Analysing the last 5-days average volume posted by the [Akebia Therapeutics Inc, AKBA], we can find that recorded value of 2.52 million was lower than the volume posted last year of 4.18 million. As of the previous 9 days, the stock’s Stochastic %D was 37.57%.
During the past 100 days, Akebia Therapeutics Inc’s (AKBA) raw stochastic average was set at 91.06%, which indicates a significant increase from 61.80% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.16 in the past 14 days, which was lower than the 0.17 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.42, while its 200-day Moving Average is $2.30. Now, the first resistance to watch is $4.00. This is followed by the second major resistance level at $4.15. The third major resistance level sits at $4.25. If the price goes on to break the first support level at $3.74, it is likely to go to the next support level at $3.64. Now, if the price goes above the second support level, the third support stands at $3.49.
Akebia Therapeutics Inc (NASDAQ: AKBA) Key Stats
The company with the Market Capitalisation of 1.01 billion has total of 262,636K Shares Outstanding. Its annual sales at the moment are 160,180 K in contrast with the sum of -69,410 K annual income. Company’s last quarter sales were recorded 57,340 K and last quarter income was 6,110 K.
